CMPS:NASDAQ
Compass Pathways PLC
$11.56
arrow_downward
-0.34%(-0.040) 1D
$11.62
arrow_upward
+0.52% (+0.060)bedtimeAfter hours
Closed: Oct 6, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CMPS...
Open
$11.72
High
$11.80
Low
$11.17
Mkt. cap
1.64B
Avg. vol.
2.77M
Volume
2.79M
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
Open
$11.72
High
$11.80
Low
$11.17
Mkt. cap
1.64B
Avg. vol.
2.77M
Volume
2.79M
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
News stories
From web sources and news partners
Washington Times
·
21 minutes ago
Wall Street profits surge as inflation and card debt stay elevated
Fox News
·
50 minutes ago
Fox News Media CEO Suzanne Scott rings Nasdaq closing bell in honor of network's 30th anniversary
PR Newswire
·
11 minutes ago
QuickLogic Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The Washington Post
·
4 minutes ago
Stocks hit record high even as consumers feel dreary
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
About Compass Pathways PLC